Open AccessNew Biological Targets in Fungi and Novel Molecule under Development: A Review
Author(s) -
Songuigama Coulibaly,
Jean-Paul D. U. N'guessan,
Alain Kacou,
Jean-Fabrice K. Koffi,
Amelanh S. Diakité,
Tanguy K. A. Kouaho,
Mahama Ouattara
Publication year - 2021
Publication title -
chemical science international journal
Language(s) - English
Resource type - Journals
ISSN - 2456-706X
DOI - 10.9734/csji/2021/v30i630235
Subject(s) - antifungal , biology , antifungal drug , drug discovery , drug resistance , drug development , computational biology , drug , biochemistry , microbiology and biotechnology , pharmacology
Antifungal therapeutics is confronted today with the challenge of drug resistance of most fungal germs to current antifungal drugs. Faced with this situation, the search for new and more efficient antifungal molecules that avoid the phenomenon of drug resistance becomes an urgent task. The design of new antifungal drugs acting on new biological targets and/or by innovative mechanisms of action is essential in the fight against fungal infections. Current advances in molecular biology have identified new targets for the development of new antifungal therapy. Several biological targets for the development of new antifungal agents are currently being explored. Amongst these, the most promising are BET (Bromodomain and Extra-Terminal) proteins, Homoserine transacetylase (HTA), mannan cell wall, Glycosylphosphatidylinositols (GPI) anchor biosynthesis, Histone deacetylases, Sphingolipid biosynthesis, D9 fatty acid desaturase and Chitin biosynthesis. This review summarizes the new biological targets and their inhibitors under development as potential new antifungal drugs.